This content is machine translated Oral JAK-i in atopic dermatitis Benefits and risks: What does the current data say? Although there have been no recent approvals of oral JAK inhibitors (JAK-i) for atopic dermatitis (AD), some interesting study findings have been published. These shed light on the safety of...…
View Post 4 min This content is machine translated Biologics for atopic dermatitis Th2 cytokines in focus: proven and new targets The range of antibody therapies for atopic dermatitis (AD) has expanded once again in Europe. In addition to dupilumab and tralokinumab, lebrikizumab is another biologic available in this country that...…
View Post 4 min This content is machine translated Basic therapy for atopic dermatitis “Emollients plus” with bacterial lysates There are various indications in the specialist literature that the gram-negative, non-pathogenic bacterium Vitreoscilla filiformis (V. filiformis) has a beneficial effect on atopic skin. New findings confirm earlier reports of...…
View Post 6 min This content is machine translated Atopic dermatitis Biologics and JAK-i – the best of both worlds In Switzerland, both the currently approved monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and the Janus kinase (JAK) inhibitors (baricitinib, abro-citinib, upadacitinib) can be used as “first-line” systemic therapy for patients with...…
View Post 6 min This content is machine translated Atopic dermatitis: "Treat-to-target" Current secondary analyses expand the evidence base In the recent past, several secondary analyses have been published in which different treatment regimes for atopic dermatitis (AD) were compared and evaluated. In order to evaluate treatment progress using…
View Post 8 min This content is machine translated Research highlights in atopic dermatitis Innovative therapies – Update 2024 The arsenal of currently researched active substances in the indication area of atopic dermatitis (AD) is considerable. In addition to anti-OX40/OX40L antibodies, CM310, nemolizumab and neurokinin receptor 1 antagonists, there…
View Post 7 min This content is machine translated Study Report S. aureus infection in pediatric AD The skin microbiome of patients with atopic dermatitis (AD) exhibits reduced bacterial diversity. The pathogen Staphylococcus aureus (S. aureus) often predominates. This gram-positive bacterium intensifies inflammatory processes and is associated…
View Post 9 min This content is machine translated Journal Club: Atopic dermatitis Modern systems therapy – status quo and prospects The therapeutic landscape for atopic dermatitis is changing. New findings have made it possible to develop modern treatment options that selectively target inflammatory signaling pathways. There are currently two modern…
View Post 4 min This content is machine translated "Small Molecules" at AD Current analyses of the pioneer among the JAK-i The first representative of the Janus kinase (JAK) inhibitor class to be approved for atopic dermatitis was baricitinib. In an extensive study program, this selective and reversible inhibitor of JAK-1…
View Post 6 min This content is machine translated Atopic dermatitis and the skin microbiome How does systemic therapy influence dysbiosis? One aim of the multicenter observational study ProRaD is to gain a better understanding of the mechanisms that influence the course of atopic dermatitis (AD). In a sub-project, researchers used…
View Post 7 min This content is machine translated Biologics for AD Interleukin-13 as a target – new long-term data available Now that the range of systemic therapeutics for atopic dermatitis has been expanded and the two monoclonal antibodies dupilumab and tralokinumab as well as three Janus kinase inhibitors have been…
